JP6154391B2 - 遺伝子改変された主要組織適合複合体マウス - Google Patents

遺伝子改変された主要組織適合複合体マウス Download PDF

Info

Publication number
JP6154391B2
JP6154391B2 JP2014539029A JP2014539029A JP6154391B2 JP 6154391 B2 JP6154391 B2 JP 6154391B2 JP 2014539029 A JP2014539029 A JP 2014539029A JP 2014539029 A JP2014539029 A JP 2014539029A JP 6154391 B2 JP6154391 B2 JP 6154391B2
Authority
JP
Japan
Prior art keywords
human
polypeptide
mhc
mouse
microglobulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014539029A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014532412A5 (OSRAM
JP2014532412A (ja
Inventor
リン マクドナルド，
リン マクドナルド，
アンドリュー ジェイ． マーフィー，
アンドリュー ジェイ． マーフィー，
ケイガン ギュラー，
ケイガン ギュラー，
ジョン ミクウィルター，
ジョン ミクウィルター，
ベラ ボロニナ，
ベラ ボロニナ，
フェイス ハリス，
フェイス ハリス，
ショーン スティーブンズ，
ショーン スティーブンズ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2014532412A publication Critical patent/JP2014532412A/ja
Publication of JP2014532412A5 publication Critical patent/JP2014532412A5/ja
Application granted granted Critical
Publication of JP6154391B2 publication Critical patent/JP6154391B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Environmental Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Husbandry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2014539029A 2011-10-28 2012-10-26 遺伝子改変された主要組織適合複合体マウス Active JP6154391B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161552587P 2011-10-28 2011-10-28
US201161552582P 2011-10-28 2011-10-28
US61/552,582 2011-10-28
US61/552,587 2011-10-28
US201261700908P 2012-09-14 2012-09-14
US61/700,908 2012-09-14
PCT/US2012/062042 WO2013063346A1 (en) 2011-10-28 2012-10-26 Genetically modified major histocompatibility complex mice

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017109327A Division JP6574457B2 (ja) 2011-10-28 2017-06-01 遺伝子改変された主要組織適合複合体マウス

Publications (3)

Publication Number Publication Date
JP2014532412A JP2014532412A (ja) 2014-12-08
JP2014532412A5 JP2014532412A5 (OSRAM) 2015-12-17
JP6154391B2 true JP6154391B2 (ja) 2017-06-28

Family

ID=47178940

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2014539029A Active JP6154391B2 (ja) 2011-10-28 2012-10-26 遺伝子改変された主要組織適合複合体マウス
JP2017109327A Active JP6574457B2 (ja) 2011-10-28 2017-06-01 遺伝子改変された主要組織適合複合体マウス
JP2019019707A Active JP6866409B2 (ja) 2011-10-28 2019-02-06 遺伝子改変された主要組織適合複合体マウス
JP2020081774A Withdrawn JP2020146041A (ja) 2011-10-28 2020-05-07 遺伝子改変された主要組織適合複合体マウス

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2017109327A Active JP6574457B2 (ja) 2011-10-28 2017-06-01 遺伝子改変された主要組織適合複合体マウス
JP2019019707A Active JP6866409B2 (ja) 2011-10-28 2019-02-06 遺伝子改変された主要組織適合複合体マウス
JP2020081774A Withdrawn JP2020146041A (ja) 2011-10-28 2020-05-07 遺伝子改変された主要組織適合複合体マウス

Country Status (27)

Country Link
US (3) US9615550B2 (OSRAM)
EP (4) EP4311833A3 (OSRAM)
JP (4) JP6154391B2 (OSRAM)
KR (3) KR101921126B1 (OSRAM)
CN (3) CN113564188B (OSRAM)
AU (3) AU2012324016C1 (OSRAM)
BR (1) BR112014009259A2 (OSRAM)
CA (2) CA2850387A1 (OSRAM)
CY (2) CY1119657T1 (OSRAM)
DK (2) DK2770821T3 (OSRAM)
ES (3) ES2741649T3 (OSRAM)
HK (1) HK1249712B (OSRAM)
HR (2) HRP20171761T1 (OSRAM)
HU (2) HUE045879T2 (OSRAM)
IL (3) IL232097A (OSRAM)
LT (2) LT2770821T (OSRAM)
MX (3) MX391222B (OSRAM)
MY (2) MY178723A (OSRAM)
NZ (1) NZ734532A (OSRAM)
PL (2) PL2770821T3 (OSRAM)
PT (2) PT2770821T (OSRAM)
RS (2) RS56656B1 (OSRAM)
SG (2) SG11201400933VA (OSRAM)
SI (2) SI2770821T1 (OSRAM)
SM (2) SMT201900478T1 (OSRAM)
WO (1) WO2013063346A1 (OSRAM)
ZA (1) ZA201403085B (OSRAM)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9591835B2 (en) 2011-10-28 2017-03-14 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex animals
PL2663575T3 (pl) 2011-10-28 2015-03-31 Regeneron Pharma Humanizowane IL-6 i receptor IL-6
LT2958938T (lt) 2013-02-20 2019-07-25 Regeneron Pharmaceuticals, Inc. Pelės, ekspresuojančios humanizuotus t ląstelių koreceptorius
EP2958937B1 (en) 2013-02-22 2018-08-15 Regeneron Pharmaceuticals, Inc. Mice expressing humanized major histocompatibility complex
US20150342163A1 (en) 2013-02-22 2015-12-03 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex mice
WO2014164640A1 (en) * 2013-03-11 2014-10-09 Regeneron Pharmaceuticals, Inc. Transgenic mice expressing chimeric major histocompatibility complex (mhc) class i molecules
PT4269430T (pt) 2013-09-23 2025-08-06 Regeneron Pharma Animais não-humanos com um gene humanizado de proteína reguladora de sinal
EP3138397B1 (en) 2013-10-15 2018-12-26 Regeneron Pharmaceuticals, Inc. Humanized il-15 animals
EP3058819B1 (en) * 2013-10-18 2021-05-19 Taiho Pharmaceutical Co., Ltd. Hla class i expressing non-human animal
EP3071025B1 (en) 2013-11-19 2018-10-10 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized a proliferation-inducing ligand gene
MX356809B (es) 2013-11-19 2018-06-13 Regeneron Pharma Animales no humanos que tienen un gen del factor activador de celulas b.
RU2700484C2 (ru) 2014-04-08 2019-09-17 Регенерон Фармасьютикалз, Инк. Не относящиеся к человеку животные, имеющие гуманизированные fc-гамма-рецепторы
MX2016014504A (es) 2014-05-05 2017-05-23 Regeneron Pharma Animales c5 y c3 humanizados.
NO2785538T3 (OSRAM) 2014-05-07 2018-08-04
CN106604635B (zh) 2014-06-19 2020-01-14 瑞泽恩制药公司 具有人源化程序性细胞死亡1基因的非人动物
RU2017113134A (ru) 2014-09-19 2018-10-19 Регенерон Фармасьютикалз, Инк. Химерные антигенные рецепторы
DK3223605T3 (da) 2014-11-24 2020-11-16 Regeneron Pharma Ikke-humane dyr, der eksprimerer humaniseret cd3-kompleks
EP3086637B1 (en) 2014-12-05 2019-01-02 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized cluster of differentiation 47 gene
MX2017007636A (es) 2014-12-09 2018-03-28 Regeneron Pharma Animales no humanos que tienen un gen del grupo de diferenciacion 274 humanizado.
US9888673B2 (en) 2014-12-10 2018-02-13 Regents Of The University Of Minnesota Genetically modified cells, tissues, and organs for treating disease
KR20240132525A (ko) 2015-04-06 2024-09-03 리제너론 파아마슈티컬스, 인크. 비인간 동물에서의 인간화 t 세포 매개 면역반응
CN107896479B (zh) * 2015-04-13 2021-07-13 再生元制药公司 人源化SIRPα-IL15敲入小鼠及其使用方法
AU2016358101B2 (en) 2015-11-20 2022-12-01 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized Lymphocyte-activation gene 3
SG10202001578RA (en) 2016-02-29 2020-04-29 Regeneron Pharma Rodents having a humanized tmprss gene
CN109640644B (zh) 2016-06-03 2021-10-26 瑞泽恩制药公司 表达外源末端脱氧核苷酸转移酶的非人动物
CN109456942A (zh) * 2017-09-06 2019-03-12 亘喜生物科技（上海）有限公司 通用型嵌合抗原受体t细胞制备技术
EP3585162B1 (en) 2017-09-29 2023-08-30 Regeneron Pharmaceuticals, Inc. Rodents comprising a humanized ttr locus and methods of use
SG11202002002XA (en) 2017-09-29 2020-04-29 Regeneron Pharma Non-human animals expressing humanized c1q complex
CA3076377A1 (en) 2017-11-30 2019-06-06 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized trkb locus
US20210051929A1 (en) 2018-03-24 2021-02-25 Regeneron Pharmaceuticals, Inc. Genetically modified non-human animals for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof
CA3093850A1 (en) 2018-03-26 2019-10-03 Regeneron Pharmaceuticals, Inc. Humanized rodents for testing therapeutic agents
SMT202400300T1 (it) 2018-07-16 2024-09-16 Regeneron Pharma Modelli di roditori della sindrome ditra e loro utilizzo
US10883084B2 (en) 2018-10-05 2021-01-05 Xenotherapeutics, Inc. Personalized cells, tissues, and organs for transplantation from a humanized, bespoke, designated-pathogen free, (non-human) donor and methods and products relating to same
CN113784615A (zh) * 2019-03-25 2021-12-10 药物治疗股份有限公司 用于从人源化的、定制的、无指定病原体的(非人)供体移植的个性化细胞、组织和器官以及与其相关的方法和制品
CN117178959A (zh) 2019-04-04 2023-12-08 瑞泽恩制药公司 包括人源化凝血因子12基因座的非人动物
AU2020286382A1 (en) 2019-06-04 2021-11-04 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized TTR locus with a beta-slip mutation and methods of use
MX2021015122A (es) 2019-06-07 2022-04-06 Regeneron Pharma Animales no humanos que comprenden un locus de albumina humanizado.
CN113105555B (zh) * 2020-01-10 2023-05-30 百奥赛图(北京)医药科技股份有限公司 Mhc分子人源化的非人动物的构建方法及应用
WO2022133155A1 (en) * 2020-12-16 2022-06-23 Xenotherapeutics, Inc. Humanization of beta2-microglobulin in porcine genome resulting in functional expression of human βeta2-microglobulin within donor cells, tissues, or organs
JP2024500399A (ja) 2020-12-16 2024-01-09 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒト化Ｆｃアルファ受容体を発現するマウス
CN118511853A (zh) 2021-03-31 2024-08-20 瑞泽恩制药公司 包含具有改善的tcrb组库多样性的人源化细胞免疫系统组分的基因修饰的小鼠
EP4536836A1 (en) 2022-06-07 2025-04-16 Regeneron Pharmaceuticals, Inc. Pseudotyped viral particles for targeting tcr-expressing cells
AU2023285085A1 (en) 2022-06-07 2024-12-19 Regeneron Pharmaceuticals, Inc. Multispecific molecules for modulating t-cell activity, and uses thereof
AU2023347224A1 (en) 2022-09-22 2025-03-20 Regeneron Pharmaceuticals, Inc. Genetically modified mice expressing components of human cellular immune system
KR20250160369A (ko) 2023-01-27 2025-11-12 리제너론 파마슈티칼스 인코포레이티드 변형된 랩도바이러스 당단백질 및 이의 용도
TW202520975A (zh) * 2023-08-09 2025-06-01 英商劍橋企業有限公司 基因改造之囓齒動物及囓齒動物細胞以及其等用途
WO2025064470A1 (en) 2023-09-19 2025-03-27 Regeneron Pharmaceuticals, Inc. Viral peptides and uses thereof
WO2025064738A1 (en) 2023-09-22 2025-03-27 Regeneron Pharmaceuticals, Inc. Dntt 250-258 off-target peptides and uses thereof
WO2025064761A1 (en) 2023-09-22 2025-03-27 Regeneron Pharmaceuticals, Inc. Kras10-18 g12d off-target peptides and uses thereof
WO2025136809A2 (en) 2023-12-19 2025-06-26 Regeneron Pharmaceuticals, Inc. Foxp3 peptides and uses thereof
WO2025178991A1 (en) 2024-02-21 2025-08-28 Regeneron Pharmaceuticals, Inc. Splicing factor gene mutation-associated neoantigenic peptides and uses thereof
WO2025212991A1 (en) 2024-04-05 2025-10-09 Regeneron Pharmaceuticals, Inc. Rodent models of disease

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US5574205A (en) 1989-07-25 1996-11-12 Cell Genesys Homologous recombination for universal donor cells and chimeric mammalian hosts
DE69033493D1 (de) 1989-07-25 2004-08-12 Cell Genesys Inc Homologe rekombination für universelle donorzellen und chimerische säugetierzellen
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9100481D0 (en) 1991-01-10 1991-02-20 Inst Nat Sante Rech Med Genetically engineered mice
AU2661692A (en) 1991-09-19 1993-04-27 President And Fellows Of Harvard College Transgenic mhc class i and class ii antigen-deficient mammals
EP0663952A4 (en) 1992-09-11 1997-06-11 Univ California Transgenic non-human animals having targeted lymphocyte transduction genes.
US5523226A (en) 1993-05-14 1996-06-04 Biotechnology Research And Development Corp. Transgenic swine compositions and methods
GB9315303D0 (en) 1993-07-23 1993-09-08 Zeneca Ltd Polypeptide
US5965787A (en) 1995-08-31 1999-10-12 Mayo Foundation For Medical Education And Research HLA-DRBI peptides with specific binding affinity for HLA-DQ molecules: prevention and treatment of rheumatoid arthritis
US6002066A (en) 1996-01-16 1999-12-14 Ortho Pharmaceutical Corp. H2-M modified transgenic mice
WO1997032603A1 (en) 1996-03-05 1997-09-12 The Scripps Research Institute Recombinant constructs encoding t cell receptors specific for human hla-restricted tumor antigens
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
ES2323098T3 (es) 1997-09-16 2009-07-06 Oregon Health And Science University Moleculas de mhc recombinantes utiles para la manipulacion de celulas t especificas de antigeno.
EP0977838B1 (en) * 1998-02-17 2004-05-26 Ortho-McNeil Pharmaceutical, Inc. H2-o modified transgenic animals
US6372955B1 (en) 1998-02-17 2002-04-16 Ortho Mcneil Pharmaceutical, Inc. Methods for Producing B cells and antibodies from H2-O modified transgenic mice
WO2001027291A1 (en) * 1999-10-12 2001-04-19 Institut Pasteur Design of a polyepitopic construct for the induction of hla-a2.1 restricted hiv 1 specific ctl responses using hhd mice
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
WO2002047474A1 (en) 2000-12-13 2002-06-20 Sumitomo Pharmaceuticals Company, Limited Transgenic animal expressing hla-a24 and utilization thereof
EP1409646B1 (en) 2000-12-19 2012-06-13 Altor BioScience Corporation Transgenic animals comprising a humanized immune system
FR2827302B1 (fr) * 2001-07-13 2003-10-10 Genoway Cellule et animal transgenique modelisant la presentation antigenique humaine et leurs utilisations
US8895020B2 (en) 2002-04-19 2014-11-25 Washington University Single chain trimers and uses therefor
US7179645B2 (en) * 2002-09-24 2007-02-20 Antigen Express, Inc. Ii-Key/antigenic epitope hybrid peptide vaccines
US7663017B2 (en) * 2003-07-30 2010-02-16 Institut Pasteur Transgenic mice having a human major histocompatability complex (MHC) phenotype, experimental uses and applications
US7745690B2 (en) 2004-03-09 2010-06-29 Nagoya Industrial Science Research Institute Transgenic nonhuman mammal representing the pathologic conditions of human rheumatoid arthritis
PL2767161T3 (pl) 2004-10-19 2018-09-28 Regeneron Pharmaceuticals, Inc. Sposób wytwarzania zwierzęcia homozygotycznego pod względem modyfikacji genetycznej
JP4830139B2 (ja) * 2006-03-10 2011-12-07 学校法人明治大学 クローン胚の作製方法
NZ547859A (en) * 2006-06-09 2009-05-31 Dec Int Nz Ltd Treatment method and composition for mastitis
EP1878342A1 (en) * 2006-07-13 2008-01-16 Institut Pasteur Immunodeficient mice transgenic for HLA class I and HLA class II molecules and their uses
EP1878798A1 (en) 2006-07-13 2008-01-16 Institut Pasteur Method of producing a multichimeric mouse and applications to study the immunopathogenesis of human tissue-specific pathologies
CA2685015A1 (en) * 2007-04-23 2008-11-06 Schering Corporation Anti-mdl-1 antibodies
TWI476280B (zh) 2008-03-07 2015-03-11 Regeneron Pharma 來自二倍體宿主胚胎注射之ｅｓ－細胞衍生的老鼠
US20090328240A1 (en) 2008-06-24 2009-12-31 Sing George L Genetically modified mice as predictors of immune response
EP2153845A1 (en) * 2008-08-13 2010-02-17 Julius-Maximilians-Universität Würzburg Endoglin peptides, vaccines and methods for preparing the same
ES2948572T3 (es) * 2009-07-08 2023-09-14 Kymab Ltd Modelos de roedores y moléculas terapéuticas
WO2012039779A1 (en) 2010-09-24 2012-03-29 The United States Of America As Represented By The Secretary Of The Navy Humanized transgenic mouse model
LT2958938T (lt) 2013-02-20 2019-07-25 Regeneron Pharmaceuticals, Inc. Pelės, ekspresuojančios humanizuotus t ląstelių koreceptorius
EP2958937B1 (en) 2013-02-22 2018-08-15 Regeneron Pharmaceuticals, Inc. Mice expressing humanized major histocompatibility complex
US20150342163A1 (en) 2013-02-22 2015-12-03 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex mice
CN105683383B (zh) * 2013-06-03 2020-08-21 赛拉福柯蒂斯公司 含有I型MHC、II型MHC或β2微球蛋白上游启动子序列的慢病毒载体
EP3058819B1 (en) * 2013-10-18 2021-05-19 Taiho Pharmaceutical Co., Ltd. Hla class i expressing non-human animal
KR20240132525A (ko) 2015-04-06 2024-09-03 리제너론 파아마슈티컬스, 인크. 비인간 동물에서의 인간화 t 세포 매개 면역반응

Also Published As

Publication number Publication date
AU2012324016C1 (en) 2018-02-15
PT2770821T (pt) 2017-12-18
EP2770821A1 (en) 2014-09-03
IL232097A0 (en) 2014-05-28
CN104039132A (zh) 2014-09-10
CY1119657T1 (el) 2018-04-04
RS56656B1 (sr) 2018-03-30
KR20180128494A (ko) 2018-12-03
ZA201403085B (en) 2025-07-30
CA2850387A1 (en) 2013-05-02
NZ719373A (en) 2018-06-29
CN107254480A (zh) 2017-10-17
WO2013063346A1 (en) 2013-05-02
EP3563680B1 (en) 2023-08-30
CN113564188B (zh) 2025-03-04
US9615550B2 (en) 2017-04-11
AU2012324016B2 (en) 2016-01-28
JP2019068857A (ja) 2019-05-09
EP2770821B1 (en) 2017-09-13
US20170164590A1 (en) 2017-06-15
US10869466B2 (en) 2020-12-22
MX376167B (es) 2025-03-07
MX391222B (es) 2025-03-21
KR102074145B1 (ko) 2020-02-07
EP3563680C0 (en) 2023-08-30
BR112014009259A2 (pt) 2020-10-27
PL3262932T3 (pl) 2019-10-31
NZ623456A (en) 2016-05-27
LT3262932T (lt) 2019-08-26
PL2770821T3 (pl) 2018-02-28
MY164836A (en) 2018-01-30
HUE035652T2 (en) 2018-05-28
SI2770821T1 (en) 2018-01-31
PT3262932T (pt) 2019-08-26
JP2017143840A (ja) 2017-08-24
ES2741649T3 (es) 2020-02-11
HRP20171761T1 (hr) 2017-12-29
SI3262932T1 (sl) 2019-09-30
US20130111617A1 (en) 2013-05-02
AU2012324016A8 (en) 2016-03-03
EP3262932A1 (en) 2018-01-03
AU2016202688A1 (en) 2016-05-19
EP4311833A2 (en) 2024-01-31
EP3563680A1 (en) 2019-11-06
JP6574457B2 (ja) 2019-09-11
HUE045879T2 (hu) 2020-01-28
SG11201400933VA (en) 2014-04-28
SMT201700576T1 (it) 2018-01-11
EP3262932B1 (en) 2019-05-15
KR20140089560A (ko) 2014-07-15
AU2016202688B2 (en) 2017-09-28
ES2962287T3 (es) 2024-03-18
MX355725B (es) 2018-04-27
CA3074400C (en) 2025-03-25
NZ734532A (en) 2022-12-23
CN107254480B (zh) 2021-08-10
KR101921126B1 (ko) 2018-11-23
JP6866409B2 (ja) 2021-04-28
RS59082B1 (sr) 2019-09-30
LT2770821T (lt) 2017-12-11
ES2651517T3 (es) 2018-01-26
MX2020010763A (es) 2022-04-01
CN113564188A (zh) 2021-10-29
SG10201603188SA (en) 2016-05-30
SMT201900478T1 (it) 2019-09-09
IL232097A (en) 2017-06-29
JP2020146041A (ja) 2020-09-17
JP2014532412A (ja) 2014-12-08
HRP20191420T1 (hr) 2019-11-15
IL252022A0 (en) 2017-06-29
HK1200272A1 (en) 2015-08-07
CY1121869T1 (el) 2020-10-14
AU2012324016A1 (en) 2013-05-16
KR20200013810A (ko) 2020-02-07
MY178723A (en) 2020-10-20
AU2017279797C1 (en) 2021-07-15
AU2017279797A1 (en) 2018-01-25
US20200375160A1 (en) 2020-12-03
CN104039132B9 (zh) 2017-09-05
IL261239A (en) 2018-10-31
CA3074400A1 (en) 2013-05-02
DK2770821T3 (da) 2017-11-27
AU2017279797B2 (en) 2020-10-22
HK1249712B (en) 2020-06-26
EP4311833A3 (en) 2024-05-01
MX2014004895A (es) 2014-09-12
IL261239B (en) 2019-11-28
CN104039132B (zh) 2017-06-16
DK3262932T3 (da) 2019-08-05
KR102295746B1 (ko) 2021-09-01

Similar Documents

Publication Publication Date Title
JP6574457B2 (ja) 遺伝子改変された主要組織適合複合体マウス
US10779520B2 (en) Genetically modified major histocompatibility complex animals
AU2012324016B8 (en) Genetically modified major histocompatibility complex mice
JP6456351B2 (ja) キメラ主要組織適合複合体（ｍｈｃ）クラスｉ分子を発現する遺伝子導入マウス
HK1249712A1 (en) Genetically modified major histocompatibility complex mice
HK40106351A (en) Genetically modified major histocompatibility complex mice
RU2783984C2 (ru) Генетически модифицированные в отношении главного комплекса гистосовместимости мыши
HK40015797A (en) Genetically modified major histocompatibility complex mice

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151026

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151026

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160906

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161206

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170502

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170601

R150 Certificate of patent or registration of utility model

Ref document number: 6154391

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250